Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by State Street Corp

State Street Corp grew its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 3.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,514,721 shares of the company’s stock after buying an additional 127,753 shares during the period. State Street Corp owned 1.14% of Amneal Pharmaceuticals worth $29,242,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. Quadrature Capital Ltd acquired a new stake in shares of Amneal Pharmaceuticals during the third quarter valued at $169,000. Polar Asset Management Partners Inc. boosted its stake in shares of Amneal Pharmaceuticals by 122.5% during the 3rd quarter. Polar Asset Management Partners Inc. now owns 393,000 shares of the company’s stock worth $3,270,000 after purchasing an additional 216,400 shares during the last quarter. Bellevue Group AG grew its holdings in shares of Amneal Pharmaceuticals by 21.8% during the third quarter. Bellevue Group AG now owns 76,414 shares of the company’s stock worth $636,000 after buying an additional 13,654 shares in the last quarter. Walleye Capital LLC purchased a new position in shares of Amneal Pharmaceuticals during the third quarter valued at approximately $1,095,000. Finally, FMR LLC lifted its stake in shares of Amneal Pharmaceuticals by 25.9% during the third quarter. FMR LLC now owns 203,510 shares of the company’s stock valued at $1,693,000 after buying an additional 41,882 shares during the period. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Trading Up 0.4 %

AMRX stock opened at $7.78 on Friday. The company has a market cap of $2.41 billion, a PE ratio of -11.44 and a beta of 1.12. The stock has a 50-day moving average price of $8.42 and a two-hundred day moving average price of $7.94. Amneal Pharmaceuticals, Inc. has a 12-month low of $5.01 and a 12-month high of $9.48.

Insider Activity

In other Amneal Pharmaceuticals news, SVP Jason B. Daly sold 43,657 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $8.61, for a total transaction of $375,886.77. Following the completion of the sale, the senior vice president now directly owns 13,665 shares in the company, valued at $117,655.65. The trade was a 76.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 26.56% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on AMRX. Truist Financial boosted their price target on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, October 2nd. Piper Sandler increased their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target for the company in a report on Friday, September 6th. Finally, StockNews.com lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $10.00.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.